A detailed history of Daiwa Securities Group Inc. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 237 shares of BPMC stock, worth $22,669. This represents 0.0% of its overall portfolio holdings.

Number of Shares
237
Previous 237 -0.0%
Holding current value
$22,669
Previous $26,000 15.38%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

SELL
$85.18 - $108.78 $340 - $435
-4 Reduced 1.66%
237 $26,000
Q4 2022

Feb 06, 2023

BUY
$41.06 - $66.48 $780 - $1,263
19 Added 8.56%
241 $11,000
Q2 2022

Aug 09, 2022

BUY
$45.23 - $70.15 $2,261 - $3,507
50 Added 29.07%
222 $11,000
Q4 2021

Feb 03, 2022

SELL
$94.25 - $115.99 $2,733 - $3,363
-29 Reduced 14.43%
172 $18,000
Q3 2021

Nov 05, 2021

BUY
$80.98 - $109.47 $6,964 - $9,414
86 Added 74.78%
201 $21,000
Q1 2021

May 03, 2021

BUY
$90.71 - $108.28 $907 - $1,082
10 Added 9.52%
115 $11,000
Q4 2020

Feb 04, 2021

SELL
$92.08 - $124.48 $18,784 - $25,393
-204 Reduced 66.02%
105 $12,000
Q3 2020

Nov 02, 2020

BUY
$66.45 - $92.7 $531 - $741
8 Added 2.66%
309 $29,000
Q1 2020

May 14, 2020

BUY
$48.11 - $82.22 $1,106 - $1,891
23 Added 8.27%
301 $18,000
Q4 2019

Jan 31, 2020

SELL
$66.73 - $82.59 $2,335 - $2,890
-35 Reduced 11.18%
278 $22,000
Q3 2019

Nov 04, 2019

BUY
$72.9 - $101.41 $437 - $608
6 Added 1.95%
313 $23,000
Q2 2019

Jul 24, 2019

BUY
$73.54 - $97.8 $1,985 - $2,640
27 Added 9.64%
307 $29,000
Q1 2019

Apr 26, 2019

BUY
$48.7 - $86.6 $1,948 - $3,464
40 Added 16.67%
280 $22,000
Q1 2018

May 02, 2018

BUY
$73.28 - $102.95 $17,587 - $24,708
240 New
240 $22,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.71B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.